⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

October 26, 2026The OncologistOpen Access

Exceptional Long-Term Responses in Metastatic Androgen Pathway-Modulation Sensitive Prostate Cancer

Varun Nandakumar Georges Gebrael Neeraj Agarwal

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Varun Nandakumar, Georges Gebrael, Neeraj Agarwal; Exceptional Long-Term Responses in Metastatic Androgen Pathway-Modulation Sensitive Prostate Cancer, The

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nandakumar et al. (2026) studied this question.

synapsesocial.com/papers/6ae2e1ad61f440a81e656af9 https://doi.org/10.1093/oncolo/oyag412

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancerReview · 2026 · 1 citations
2Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient2024 · 2 citations
3Clinical characteristics and long-term outcomes of extreme responders to first line treatment of metastatic prostate cancer.Human Clinical Trial · 2026
4Abstract 5705: Identifying androgen deprivation-induced responses in prostate cancer with single cell multiomic analysisOriginal Research · 2026
5Long-term outcomes and treatment cessation in patients with long term response to first line treatment of metastatic prostate cancerCohort Study · 2026
6PD57-11 MOLECULAR PATHWAY ALTERATIONS FOLLOWING NEOADJUVANT PROSTATE RADIOTHERAPY IN A PROSPECTIVE TRIAL2024
7Abstract 3143: Co-targeting of two distinct androgen receptor-regulated signaling pathways as a therapeutic approach in prostate cancerOriginal Research · 2026
8Abstract 2697: Single-cell transcriptomic characterisation reveals pathway determinants of bipolar androgen therapy response in prostate cancer.Original Research · 2026
9TAVO412, an Anti-EGFR, cMET and VEGF Trispecific Antibody: Initial Results from a Phase I Dose Escalation Study in Patients with Advanced Solid TumorsThe Oncologist · 2026
10Tumor Longevity: a time-dependent biomarker of immune checkpoint inhibitor responsiveness across head and neck, lung, renal and urothelial cancersThe Oncologist · 2026

More from The Oncologist

More from Dana-Farber Cancer Institute

More from University of Utah

More from Huntsman Cancer Institute